首页> 外文期刊>Antimicrobial agents and chemotherapy. >Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains
【24h】

Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains

机译:Ceftazidime-Avibactam活性对来自美国医院(2011年至2013年)(2011年至2013年)的肠杆菌膜分离株以及β-内酰胺酶产生菌株的表征

获取原文
获取原文并翻译 | 示例
           

摘要

Ceftazidime-avibactam (MIC50/90, 0.12/0.25 μg/ml) inhibited 99.9% (20,698/20,709) of Enterobacteriaceae isolates at ≤8 μg/ml. This compound was active against resistant subsets, including ceftazidime-nonsusceptible Enterobacter cloacae (MIC50/90, 0.25/0.5 μg/ml) and extended-spectrum β-lactamase (ESBL) phenotype isolates. An ESBL phenotype was noted among 12.4% (1,696/13,692 isolates from targeted species) of the isolates, including 776 Escherichia coli (12.0% for this species; MIC50/90, 0.12/0.25 μg/ml), 721 Klebsiella pneumoniae (16.3%; MIC50/90, 0.12/0.25 μg/ml), 119 Klebsiella oxytoca (10.3%; MIC50/90, 0.06/0.25 μ/ml), and 80 Proteus mirabilis (4.9%; MIC50/90, 0.06/0.12 μg/ml) isolates. The most common enzymes detected among ESBL phenotype isolates from 2013 (n = 743) screened using a microarray-based assay were CTX-M-15-like (n = 307), KPC (n = 120), SHV ESBLs (n = 118), and CTX-M-14-like (n = 110). KPC producers were highly resistant to comparators, and ceftazidime-avibactam (MIC50/90, 0.5/2 μg/ml) and tigecycline (MIC50/90, 0.5/1 μg/ml; 98.3% susceptible) were the most active agents against these strains. Meropenem (MIC50/90, ≤0.06/≤0.06 μg/ml) and ceftazidime-avibactam (MIC50/90, 0.12/0.25 μg/ml) were active against CTX-M-producing isolates. Other enzymes were also observed, and ceftazidime-avibactam displayed good activity against the isolates producing less common enzymes. Among 11 isolates displaying ceftazidime-avibactam MIC values of >8 μg/ml, three were K. pneumoniae strains producing metallo-β-lactamases (all ceftazidime-avibactam MICs, >32 μg/ml), with two NDM-1 producers and one K. pneumoniae strain carrying the blaKPC-2 and blaVIM-4 genes. Therapeutic options for isolates producing β-lactamases may be limited, and ceftazidime-avibactam, which displayed good activity against strains, including those producing KPC enzymes, merits further study in infections where such organisms occur. Copyright ? 2015, American Society for Microbiology. All Rights Reserved.
机译:Ceftazidime-Avibactam(MIC50 / 90,0.2 /0.25μg/ ml)抑制99.9%(20,698 / 20,709)的肠杆菌区分离物,≤8μg/ ml。该化合物对抗抗性子集是活性的,包括头孢他啶 - 非肌肉内切霉菌(MIC50 / 90,0.25 /0.5μg/ ml)和扩展光谱β-内酰胺酶(ESBL)表型分离物。在分离物的12.4%(来自靶标​​物种的1,696 / 13,692分离物)中,包括776个大肠杆菌(该物种12.0%; MIC50 / 90,0.12 /0.25μg/ ml),721克尔布氏菌(16.3%)(16.3%)(16.3%)(16.3%) ; MIC50 / 90,0.12 /0.25μg/ ml),119克尔布氏菌(10.3%; MIC50 / 90,0.06 /0.25μm/ ml)和80个蛋白质mirabilis(4.9%; MIC50 / 90,0.06 /0.12μg/ ml )隔离。使用微阵列的测定从2013(n = 743)筛选的ESBL表型分离物中检测到的最常见酶是CTX-M-15样(n = 307),KPC(n = 120),SHV ESBL(n = 118 )和CTX-M-14样(n = 110)。 KPC生产者对比较器具有高度耐药,CeTTazidime-Avibactam(MIC50 / 90,0.5 /2μg/​​ mL)和替霉素(MIC50 / 90,0.5 /1μg/ mL; 98.3%易感)是对这些菌株最活跃的药剂。梅洛宁(MIC50 / 90,≤0.06/≤0.06μg/ ml)和CeTtazidime-Avibactam(MIC50 / 90,0.12 /0.25μg/ ml)对抗CTX-M产生分离物。还观察到其他酶,并且Ceftazidime-Avibactam针对产生不太常见的酶的分离物显示出良好的活性。在11个分离物中,显示Ceftazidime-Avibactam MIC值>8μg/ ml,三种是K.肺炎肺菌株生产金属-β-内酰胺酶(所有头孢唑米 - Avibactam Mics,>32μg/ ml),具有两个Ndm-1生产商和一个K.患有Blakpc-2和Blavim-4基因的肺炎菌株。产生β-内酰胺酶的分离物的治疗选择可以是有限的,并且Ceftazidime-Avibactam,其针对产生KPC酶的菌株的良好活性显示出良好的活性,可进一步研究这种生物体发生的感染。版权? 2015年,美国微生物学会。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号